NCT05334069 · Alliance for Clinical Trials in Oncology
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
What this study is about
This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in the laboratory may help researchers develop tests for the early detection of cancers.
View original scientific description
This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in the laboratory may help researchers develop tests for the early detection of cancers.
Who can participate
This study lists these criteria on ClinicalTrials.gov. A study coordinator reviews eligibility during screening — this page does not determine whether you qualify.
Inclusion criteria
- Participants with a cancer diagnosis: Documentation of disease:
- Histologic documentation: Histologically confirmed diagnosis of invasive cancer
- Stage: Stage I-IV per American Joint Committee on Cancer (AJCC) 7th edition, with the exception of patients with leukemia, lymphoma, and multiple myeloma
- For leukemia: Type (chronic lymphocytic leukemia \[CLL\], chronic myeloid leukemia \[CML\], acute lymphoblastic lymphoma \[ALL\], acute myeloid leukemia \[AML\])
- For lymphoma: Stage I-IV based on Ann Arbor staging
- For multiple myeloma: Stage I, II, III based on Revised International Staging System (RISS)
- One of the following tumor types:
- Head and neck
- Hepatobiliary
- Ovary \*\*\
- For these specific cancer types only, patients may be enrolled prior to histologic confirmation of malignancy. Sites are required to contact the study chairs to review appropriateness for enrollment
- Pancreas \*\*\
- For these specific cancer types only, patients may be enrolled prior to histologic confirmation of malignancy. Sites are required to contact the study chairs to review appropriateness for enrollment
- Multiple myeloma
- Gastric, esophageal or gastroesophageal
- For these specific cancer types only, patients may be enrolled prior to histologic confirmation of malignancy. Sites are required to contact the study chairs to review appropriateness for enrollment
- Endometrium
- Melanoma \*\*\
- For these specific cancer types only, patients may be enrolled prior to histologic confirmation of malignancy. Sites are required to contact the study chairs to review appropriateness for enrollment
- Participants with a cancer diagnosis: No prior definitive systemic or local anti-cancer intervention
- Participants with a cancer diagnosis: Age \>= 40 and =\< 75
- Participants with a cancer diagnosis: No known current pregnancy by self-report
- Participants with a cancer diagnosis: No known or prior history of in situ or invasive malignancy (excluding in situ non-melanoma skin cancers) other than the current cancer diagnosis
- Participants with a cancer diagnosis: Willingness to provide blood samples for research use
- Participants with a cancer diagnosis: Absence of medical contraindications to a research blood draw volume of 60 mL
- Participants with a cancer diagnosis: No history of organ transplantation
- Participants with a cancer diagnosis: Ability to read and comprehend English or Spanish \
- Eligibility is restricted to individuals who can comprehend and read English or Spanish given that participation in the study will require the ability to read and complete questionnaires that are available only in those two languages
- Participants without a cancer diagnosis and without suspicion of cancer: Age \>= 40 and =\< 75
- Participants without a cancer diagnosis and without suspicion of cancer: No known current pregnancy by self-report
- Participants without a cancer diagnosis and without suspicion of cancer: No known or prior history of in situ or invasive malignancy (excluding in situ non-melanoma skin cancers)
- Participants without a cancer diagnosis and without suspicion of cancer: Willingness to provide blood samples for research use
- Participants without a cancer diagnosis and without suspicion of cancer: Absence of medical contraindications to a research blood draw volume of 60 mL
- Participants without a cancer diagnosis and without suspicion of cancer: No history of organ transplantation
- Participants without a cancer diagnosis and without suspicion of cancer: Ability to read and comprehend English or Spanish \
- Eligibility is restricted to individuals who can comprehend and read English or Spanish given that participation in the study will require the ability to read and complete questionnaires that are available only in those two languages
- Participants with a high suspicion of cancer: High suspicion of ovarian cancer, pancreatic cancer, kidney cancer, or melanoma by clinical and/or radiological assessment, with plans for histologic or cytologic confirmation within 28 days after study blood draw \
- Examples of highly suspicious cases include: elevated CA125 and abnormal transvaginal ultrasound, suspicious renal or pancreatic mass on imaging, suspicious cutaneous lesion concerning for melanoma
- Participants with a high suspicion of cancer: Central review of radiology reports and/or clinical documentation conducted by study chairs
- Participants with a high suspicion of cancer: Age \>= 40 and =\< 75
- Participants with a high suspicion of cancer: No known current pregnancy by self-report
- Participants with a high suspicion of cancer: No known or prior history of in situ or invasive malignancy (excluding in situ non-melanoma skin cancers) other than the current cancer diagnosis
- Participants with a high suspicion of cancer: Willingness to provide blood samples for research use
- Participants with a high suspicion of cancer: Absence of medical contraindications to a research blood draw volume of 60 mL
- Participants with a high suspicion of cancer: No history or organ transplantation
- Participants with a high suspicion of cancer: Ability to read and comprehend English or Spanish \
- Eligibility is restricted to individuals who can comprehend and read English and Spanish given that participation in the study will require the ability to read and complete questionnaires that are available only in those two languages
Where
- Anchorage, Alaska
- Fairbanks, Alaska
- Kingman, Arizona
- Phoenix, Arizona
- Fort Smith, Arkansas
- Little Rock, Arkansas
- Arroyo Grande, California
- Bakersfield, California
- Burbank, California
- Carmichael, California
- Concord, California
- Dublin, California
And 492 more locations — see the full list below.
Frequently asked questions
What is a clinical trial?
A clinical trial is a research study that tests new medical treatments, drugs, devices, or procedures to determine their safety and effectiveness. Trials are carefully designed and monitored to protect participants while advancing medical knowledge.
Is it safe to participate?
Clinical trials follow strict safety guidelines and ethical standards. Trials must be reviewed and approved, and participants are closely monitored by medical professionals throughout the study. You can withdraw at any time if you choose.
Will I be compensated?
Many clinical trials offer compensation for your time, travel expenses, and inconvenience. The specific compensation varies by study and will be discussed during the screening process. All study-related medical care is typically provided at no cost to participants.
Will I receive a placebo instead of treatment?
When effective treatment exists, participants typically receive either the standard treatment plus the study intervention, or the standard treatment plus placebo. You would not be denied effective care. Placebos are primarily used when no proven treatment is available, or in addition to standard care. Your trial consent form will clearly explain what treatments you may receive.
Can I leave a trial if I change my mind?
Absolutely. Participation in clinical trials is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty or loss of benefits to which you are otherwise entitled.
How long does a clinical trial last?
Trial duration varies widely depending on the study design and purpose. Some trials last just a few weeks, while others may continue for months or years. The study coordinator will provide specific timeline information during your screening call.
Data: ClinicalTrials.gov · synced Jul 2, 2026 · Source of record for eligibility and locations